Trials / Completed
CompletedNCT04551586
A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
A Phase 1 Study to Assess the Relative Bioavailability of ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This will be an open-label, 3-sequence, 3-period crossover study in healthy adult participants to assess the relative bioavailability of ACH-0145228 when administered as an immediate release tablet versus powder-in-capsule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACH-0145228: Immediate Release | ACH-0145228 (240 milligrams) will be administered orally on Day 1. |
| DRUG | ACH-0145228: Powder-in-capsule | ACH-0145228 (240 milligrams) will be administered orally on Day 1. |
Timeline
- Start date
- 2020-06-26
- Primary completion
- 2020-10-19
- Completion
- 2020-10-19
- First posted
- 2020-09-16
- Last updated
- 2021-12-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04551586. Inclusion in this directory is not an endorsement.